ProBioGen, a Contract Development & Manufacturing Organization (CDMO), has partnered with DIOSynVax Ltd to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever (HF) vaccine that was developed in collaboration with the Molecular Virology, Institute of Medical Microbiology and Hygiene, University of Regensburg.   The novel vaccine targets HF diseases caused by Ebola, Marburg, and Lassa viruses. The pre-clinical efficacy of the novel trivalent vaccine has been demonstrated in challenge stud...